difference between glp 1 and tirzepatide Bridging the gap GLP1-receptor agonists cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Semaglutide vs Tirzepatide: Understanding GLP-1

Patients should discuss with their primary care physician and/or endocrinologist whether they should cease GLP-1 medication use in order to balance the risk of vision loss from NAION in the fellow eye with the hypoglycemic and cardiovascular benefits from treatment

If constipation keeps coming back, one high-fiber breakfast may not be enough

But the source of this sea change is not the economy or a global pandemic but rather a medication: specifically GLP-1s

Long-term semaglutide therapy (2+ years) has been studied and shown to be safe in clinical trials, with benefits to weight, blood sugar, and cardiovascular markers

Other than saroglitazar, elafibranor, a PPAR / agonist, was tested in a 1-year phase II RCT involving 274 subjects with biopsy-proven NASH, 107 of whom were diabetic: using a modified post hoc primary endpoint, elafibranor resolved NASH in a significant percentage of patients, without worsening of fibrosis, and ameliorated the hepatic and metabolic profile [67]